Clinical course of idiopathic inflammatory myopathies in the COVID-19 pandemic: a single-center experience

Apaydin H., Erden A., Güven S. C., Armağan B., Karakaş Ö., Özdemir B., ...More

Future Virology, vol.17, no.8, pp.545-556, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17 Issue: 8
  • Publication Date: 2022
  • Doi Number: 10.2217/fvl-2021-0146
  • Journal Name: Future Virology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE
  • Page Numbers: pp.545-556
  • Keywords: corticosteroids, hydroxychloroquine, idiopathic inflammatory myopathies, immunosuppression, myositis, SARS-CoV-2
  • Gazi University Affiliated: No

Abstract

© 2022 Future Medicine Ltd.Aim: To evaluate the clinical course of idiopathic inflammatory myopathy (IIM) patients in COVID-19 pandemic, and to assess the COVID-19 outcomes in infected IIM patients. Materials & methods: In this study, 39 patients were evaluated retrospectively. Myositis disease activity, myositis damage index, depression, fatigue, active medical treatment, drug compliance and SARS-CoV-2 PCR test results in COVID-19 pandemic were collected. Results: Fourteen of these patients (35%) were detected to have a positive SARS-CoV-2 PCR test. The demographic and clinical characteristics, active medical treatment, disease activity, depression and fatigue of the patients who had undergone or not SARS-CoV-2 were similar. Conclusion: Our results have shown that although prevalence of COVID-19 seems to be increased in IIM patients under immunosuppressive treatment, hospitalization rates were lower and no intensive care unit admissions or deaths were observed.